{"filing":{"accession_number":"0001193125-26-333827","cik":"0001936258","ticker":"NAMSW","company_name":"NewAmsterdam Pharma Co N.V.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"nams-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-20260805.htm"},"events":[{"id":24479,"run_id":22182,"accession_number":"0001193125-26-333827","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"NewAmsterdam Pharma issued a press release on August 5, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($678.3 million), revenue ($3.7 million), R\u0026D expenses ($41.7 million), SG\u0026A expenses ($26.9 million), and net loss ($64.1 million). The disclosure is a standard quarterly earnings announcement with detailed financial metrics and operational updates, furnished as Exhibit 99.1 under Item 2.02.","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25042,"accession_number":"0001193125-26-333827","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NewAmsterdam Pharma issued a press release on August 5, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($678.3 million), revenue ($3.7 million), R\u0026D expenses ($41.7 million), SG\u0026A expenses ($26.9 million), and net loss ($64.1 million). The disclosure is a standard quarterly earnings announcement with detailed financial metrics and operational updates, furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:39:15.587784+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25042,"accession_number":"0001193125-26-333827","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NewAmsterdam Pharma issued a press release on August 5, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($678.3 million), revenue ($3.7 million), R\u0026D expenses ($41.7 million), SG\u0026A expenses ($26.9 million), and net loss ($64.1 million). The disclosure is a standard quarterly earnings announcement with detailed financial metrics and operational updates, furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:39:15.587784+00:00","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-08-05"}]}